|
|
| (11 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #Redirect [[High density lipoprotein classification]] |
| {{High density lipoprotein}}
| |
| {{CMG}} ;{{AE}} {{MM}}
| |
| | |
| ==Overview==
| |
| Low HDL level cut-off point has been a debate in many surveys. Most recently, it was set to be below 1.0 mmol/L (40 mg/dL), both in men and women.<ref name="pmid12485966">{{cite journal| author=National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)| title=Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. | journal=Circulation | year= 2002 | volume= 106 | issue= 25 | pages= 3143-421 | pmid=12485966 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12485966 }} </ref>
| |
| | |
| ==Definition==
| |
| HDL low level cut point has been subjected recently to variable changes. In the Pan-European survey of HDL-cholesterol set out to determine the prevalence of low HDL-cholesterol, they defined the low HDL cut-off by levels below 1.03 mmol/L (40 mg/dL) in men, and 1.29 mmol/L (50 mg/dL)in women.<ref>{{Cite web | last = | first = | title = Defining the prevalence of low HDL-C in a European cohort of dyslipidaemic patients | url = http://eurheartjsupp.oxfordjournals.org/content/7/suppl_F/F23.full?sid=70412a9e-1bf7-486e-90a9-0ae32b4ad6b1 | publisher = | date = | accessdate = 20 September 2013 }} </ref> The clear risk of cardiovascular disease at levels above 35 mg/dL led the [[Adult Treatment Panel guidelines|ATP III]] panel to recognize a higher cut-off for low HDL, they considered a level <40 mg/dL in both men and women. [[Adult Treatment Panel guidelines|ATP III]] also rejected the idea to Set a different cut-point for low HDL cholesterol in men and women, and explained this rejection that it would make many women who are otherwise at low risk eligible for LDL-lowering drugs.<ref name="pmid12485966">{{cite journal| author=National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)| title=Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. | journal=Circulation | year= 2002 | volume= 106 | issue= 25 | pages= 3143-421 | pmid=12485966 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12485966 }} </ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Lipopedia}}
| |
| | |
| [[Category:Lipopedia]]
| |
| [[Category:Lipid disorders]]
| |
| [[Category:Cardiology]]
| |
| [[Category:Lipoproteins]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |